# Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations

> **NCT06511648** · PHASE2 · RECRUITING · sponsor: **Spanish Oncology Genito-Urinary Group** · enrollment: 90 (estimated)

## Conditions studied

- Muscle-invasive Bladder Cancer

## Interventions

- **DRUG:** Erdafitinib monotherapy
- **DRUG:** Cetrelimab and Erdafitinib combination

## Key facts

- **NCT ID:** NCT06511648
- **Lead sponsor:** Spanish Oncology Genito-Urinary Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-07
- **Primary completion:** 2026-07
- **Final completion:** 2029-10
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-12-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06511648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06511648, "Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06511648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*